GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Enzymatica AB (OSTO:ENZY) » Definitions » Enterprise Value

Enzymatica AB (OSTO:ENZY) Enterprise Value : kr967.30 Mil (As of Apr. 01, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Enzymatica AB Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Enzymatica AB's Enterprise Value is kr967.30 Mil. Enzymatica AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was kr-51.43 Mil. Therefore, Enzymatica AB's EV-to-EBIT ratio for today is -18.81.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Enzymatica AB's Enterprise Value is kr967.30 Mil. Enzymatica AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was kr-51.43 Mil. Therefore, Enzymatica AB's EV-to-EBITDA ratio for today is -18.81.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Enzymatica AB's Enterprise Value is kr967.30 Mil. Enzymatica AB's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was kr45.58 Mil. Therefore, Enzymatica AB's EV-to-Revenue ratio for today is 21.22.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Enzymatica AB's Enterprise Value is kr967.30 Mil. Enzymatica AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was kr-60.90 Mil. Therefore, Enzymatica AB's EV-to-FCF ratio for today is -15.88.


Enzymatica AB Enterprise Value Historical Data

The historical data trend for Enzymatica AB's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzymatica AB Enterprise Value Chart

Enzymatica AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,661.26 1,276.07 710.78 657.70 309.49

Enzymatica AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 657.70 564.58 469.77 367.93 309.49

Competitive Comparison of Enzymatica AB's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, Enzymatica AB's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzymatica AB's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enzymatica AB's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Enzymatica AB's Enterprise Value falls into.


;
;

Enzymatica AB Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Enzymatica AB's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as

Enzymatica AB's Enterprise Value for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enzymatica AB  (OSTO:ENZY) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Enzymatica AB's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=967.301/-51.432
=-18.81

Enzymatica AB's current Enterprise Value is kr967.30 Mil.
Enzymatica AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-51.43 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Enzymatica AB's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=967.301/-51.432
=-18.81

Enzymatica AB's current Enterprise Value is kr967.30 Mil.
Enzymatica AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-51.43 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Enzymatica AB's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=967.301/45.576
=21.22

Enzymatica AB's current Enterprise Value is kr967.30 Mil.
Enzymatica AB's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr45.58 Mil.

4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Enzymatica AB's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=967.301/-60.901
=-15.88

Enzymatica AB's current Enterprise Value is kr967.30 Mil.
Enzymatica AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-60.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enzymatica AB Enterprise Value Related Terms

Thank you for viewing the detailed overview of Enzymatica AB's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzymatica AB Business Description

Traded in Other Exchanges
N/A
Address
Scheelevagen 19, Delta 5, Ideon Science Park, Lund, SWE, SE-223 70
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.

Enzymatica AB Headlines

From GuruFocus

Tiger Management Founder Julian Robertson Ups Stake in Enzymotec

By Kyle Ferguson Kyle Ferguson 12-07-2015

Julian Robertson Cuts Half of Stake in Paulson-Backed Company

By Holly LaFon Holly LaFon 07-01-2016

Julian Robertson Adds to Multiple Positions in 3rd quarter

By Tiziano Frateschi Tiziano Frateschi 12-20-2016